Adam Giermasz, M.D., Ph.D.

Adam Giermasz, M.D., Ph.D.


Internal Medicine


Adult Hemophilia


  • Assistant Professor
To see if Adam Giermasz is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Midtown Ambulatory Care Center

3160 Folsom Blvd, Suite 3900
Sacramento, CA 95816
Driving Directions

Primary Phone:

Additional Phone Numbers

Clinic Phone: 916-734-3461 Clinic Appointments
Clinic Fax: 916-734-3591
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Philosophy of Care

My Philosophy is to educate my patients and their families so they may participate fully in decisions about their care.  I strive to care in an environment that is open and accepting.

Clinical Interests

Dr. Giermasz is a board certified hematologist who specializes in adult hemophilia.

Research/Academic Interests

Dr. Giermasz's research interests include: hemophilia, bleeding disorders and thrombosis.


Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center


M.D., Medical University of Warsaw, Warsaw Poland 1998

Ph.D., Molecular Medicine, Medical University of Warsaw, Warsaw Poland 2002

III Secondary School - Lyceum, Warsaw Poland 1992


Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh PA 2006-2008


Hematology Oncology, UC San Francisco Medical Center, San Francisco CA 2008-2011

Board Certifications

American Board of Internal Medicine, 2008

American Board of Internal Medicine, Hematology, 2012

Professional Memberships

American Society of Hematology (ASH)

International Society on Thrombosis and Haemostasis

Select Recent Publications

Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz A, Kalinski P, Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine. 2012 Mar 30;30(16):2633-9.

Giermasz A, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009 Aug;58(8):1329-36.

Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res. 2007 Oct 15;67(20):10012-8.

Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res. 2006;36(1-3):137-46.

Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005; 42(4): 535-9.

Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 2005; 5(10):1303-15.

Maiiliard RB, Son Y-I, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003; 171(5): 2366-73.

O’Connell PJ, Son Y-I, Giermasz A, Wang Z, Logar AJ, Thomson A, Kalinski P. Type-1 polarized - -dependent deifferences offset -related dendritic cell heterogeneity. Eur J Immunol 2003; 33(7): 2007-13.

Stoklosa T, Golab J, Wojcik C, Wlodarski P. Jalili A, Januszko A, Giermasz A, Wilczynski GM, Pleban E, Marczak M, Wilk S, Jakobisiak M. Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. Apoptosis 2004; 9: 193-204.